Earnings
Nuvectis CEO Expects FDA To Demand A New U.S. Study Of Its China-Approved PNH Pill
Ron Bentsur says a U.S. trial of ciprocopan is the realistic outcome, with an update on the FDA path due by year end.
Nuvectis Pharma (NVCT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Ron Bentsur says a U.S. trial of ciprocopan is the realistic outcome, with an update on the FDA path due by year end.
SEC Filings
The drug developer says none of the contingent payments to its China-based licensor were considered probable as of September 30, 2026.
SEC Filings
The drug developer holds $140.7 million in cash and says it can fund operations into the second half of 2029.